184 related articles for article (PubMed ID: 26563191)
1. Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts.
Serrill JD; Wan X; Hau AM; Jang HS; Coleman DJ; Indra AK; Alani AW; McPhail KL; Ishmael JE
Invest New Drugs; 2016 Feb; 34(1):24-40. PubMed ID: 26563191
[TBL] [Abstract][Full Text] [Related]
2. Coibamide A induces mTOR-independent autophagy and cell death in human glioblastoma cells.
Hau AM; Greenwood JA; Löhr CV; Serrill JD; Proteau PJ; Ganley IG; McPhail KL; Ishmael JE
PLoS One; 2013; 8(6):e65250. PubMed ID: 23762328
[TBL] [Abstract][Full Text] [Related]
3. Improved Total Synthesis and Biological Evaluation of Coibamide A Analogues.
Yao G; Wang W; Ao L; Cheng Z; Wu C; Pan Z; Liu K; Li H; Su W; Fang L
J Med Chem; 2018 Oct; 61(19):8908-8916. PubMed ID: 30247036
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.
Xu P; Wang H; Pan H; Chen J; Deng C
Cancer Chemother Pharmacol; 2022 Feb; 89(2):183-196. PubMed ID: 34997858
[TBL] [Abstract][Full Text] [Related]
5. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.
Li MY; Lv YC; Tong LJ; Peng T; Qu R; Zhang T; Sun YM; Chen Y; Wei LX; Geng MY; Duan WH; Xie H; Ding J
Acta Pharmacol Sin; 2016 Mar; 37(3):398-407. PubMed ID: 26806300
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
7. Coibamide A, a potent antiproliferative cyclic depsipeptide from the Panamanian marine cyanobacterium Leptolyngbya sp.
Medina RA; Goeger DE; Hills P; Mooberry SL; Huang N; Romero LI; Ortega-Barría E; Gerwick WH; McPhail KL
J Am Chem Soc; 2008 May; 130(20):6324-5. PubMed ID: 18444611
[TBL] [Abstract][Full Text] [Related]
8. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
[TBL] [Abstract][Full Text] [Related]
9. Coibamide A kills cancer cells through inhibiting autophagy.
Shi W; Lu D; Wu C; Li M; Ding Z; Li Y; Chen B; Lin X; Su W; Shao X; Xia Z; Fang L; Liu K; Li H
Biochem Biophys Res Commun; 2021 Apr; 547():52-58. PubMed ID: 33592379
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of the [d-MeAla(11)]-epimer of coibamide A.
Nabika R; Suyama TL; Hau AM; Misu R; Ohno H; Ishmael JE; McPhail KL; Oishi S; Fujii N
Bioorg Med Chem Lett; 2015 Jan; 25(2):302-6. PubMed ID: 25488840
[TBL] [Abstract][Full Text] [Related]
11. Berberine inhibits angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway.
Jin F; Xie T; Huang X; Zhao X
Pharm Biol; 2018 Dec; 56(1):665-671. PubMed ID: 31070539
[TBL] [Abstract][Full Text] [Related]
12. Depsipeptide companeramides from a Panamanian marine cyanobacterium associated with the coibamide producer.
Vining OB; Medina RA; Mitchell EA; Videau P; Li D; Serrill JD; Kelly JX; Gerwick WH; Proteau PJ; Ishmael JE; McPhail KL
J Nat Prod; 2015 Mar; 78(3):413-20. PubMed ID: 25562664
[TBL] [Abstract][Full Text] [Related]
13. Rhamnazin, a novel inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy.
Yu Y; Cai W; Pei CG; Shao Y
Biochem Biophys Res Commun; 2015 Mar; 458(4):913-9. PubMed ID: 25704088
[TBL] [Abstract][Full Text] [Related]
14. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
Niu G; Sun L; Pei Y; Wang D
Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
[TBL] [Abstract][Full Text] [Related]
15. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
[TBL] [Abstract][Full Text] [Related]
16. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
17. ATG5 Promotes Death Signaling in Response to the Cyclic Depsipeptides Coibamide A and Apratoxin A.
Wan X; Serrill JD; Humphreys IR; Tan M; McPhail KL; Ganley IG; Ishmael JE
Mar Drugs; 2018 Mar; 16(3):. PubMed ID: 29494533
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
19. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
